GSK: story ‘unfair'

Share this article:
GlaxoSmithKline's director of CME took exception with a Wall Street Journal report on GSK-funded med ed.

The December 2006 article asserts that GSK paid for a series of lectures by doctors who favor universal screening and treatment of pregnant women for genital herpes (MM&M, January 2007), two contentious issues.

“Your article implies that the industry uses [CME] as a means to promote product; this unfairly taints the value that quality CME brings to healthcare professionals and to the patients,” wrote Bryan King, PharmD, director, GSK Center for Medical Education, in a letter to the editor.
GSK's Valtrex is not approved to prevent neonatal herpes in pregnant women.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.